CSCIF (Cosciens Biopharma) Inventories, Raw Materials & Components: $0.49 Mil (As of Mar. 2026)


CSCIF Cosciens Biopharma Inc CSCIF
62 GF Score
Price $1.99
GF Value $2.35
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Inventories, Raw Materials & Components?

Cosciens Biopharma CSCIF -5.24% 62 Inventories, Raw Materials & Components is $0.49 Mil as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Cosciens Biopharma's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $0.49 Mil.

Cosciens Biopharma's quarterly raw materials declined from Sep. 2025 ($0.66 Mil) to Dec. 2025 ($0.59 Mil) and declined from Dec. 2025 ($0.59 Mil) to Mar. 2026 ($0.49 Mil).

Cosciens Biopharma's annual raw materials declined from Dec. 2023 ($0.88 Mil) to Dec. 2024 ($0.74 Mil) and declined from Dec. 2024 ($0.74 Mil) to Dec. 2025 ($0.59 Mil).

Cosciens Biopharma Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Inventories, Raw Materials & Components Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.64 0.88 0.74 0.59

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.78 0.66 0.59 0.49
CSCIF
62GF Score
Cosciens Biopharma Inc CSCIF
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.49 Mil mean?
Cosciens Biopharma (CSCIF) has a Inventories, Raw Materials & Components of $0.49 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Inventories, Raw Materials & Components too high?
Cosciens Biopharma's current Inventories, Raw Materials & Components is $0.49 Mil. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Inventories, Raw Materials & Components compare to VRTX and REGN?
Cosciens Biopharma's Inventories, Raw Materials & Components of $0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Inventories, Raw Materials & Components is $0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current Inventories, Raw Materials & Components is $0.49 Mil. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Inventories, Raw Materials & Components is $0.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Inventories, Raw Materials & Components: $0.49 Mil
  • GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score

Get the complete analysis for CSCIF

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price
$2.35
GF Value